

22 September 2011

Proposal to amend the terms of listing for efavirenz

Following a request to pharmaceutical suppliers for commercial proposals as an alternative to tendering certain pharmaceuticals for sole supply, PHARMAC and Merck Sharp and Dohme (New Zealand) Limited (MSD) have entered into a provisional agreement that would amend the terms of listing of efavirenz (Stocrin). PHARMAC is now seeking feedback on this proposal.

Details of the proposal

- Stocrin would be listed in Part II of Section H of the Pharmaceutical Schedule and remain listed in Section B of the Pharmaceutical Schedule from 1 January 2012 at the following prices and subsidies (ex-manufacturer, excluding GST):

| Chemical | Presentation | Brand | Pack size | Price and subsidy |
|-----------|---------------|---------|-----------|-------------------|
| Efavirenz | 50 mg tablet | Stocrin | 30 | \$158.33 |
| Efavirenz | 200 mg tablet | Stocrin | 90 | \$474.99 |
| Efavirenz | 600 mg tablet | Stocrin | 30 | \$474.99 |

- A confidential rebate would apply to all community dispensing of Stocrin which would reduce its net price.
- All presentations of Stocrin would have subsidy and delisting protection until 30 June 2015.
- Stocrin would remain funded in the community subject to the Special Authority currently applying to all antiretrovirals

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Thursday, 6 October 2011** to:

Greg Williams
 Therapeutic Group Manager
 PHARMAC
 PO Box 10 254
 Wellington 6143

Email: Greg.Williams@pharmac.govt.nz

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Acting Chief Executive acting under delegated authority) prior to making a decision on this proposal.